Search Medical Condition
Please enter condition
Please choose location

Lorient Cedex, France Clinical Trials

A listing of Lorient Cedex, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (84) clinical trials

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as ...

Phase

0.0 miles

Learn More »

Nintedanib (Vargatef ) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer

59 Patients with histologically documented stage IV NSCLC no squamous, after failure of first line chemotherapy and refractory (progressive disease during first line chemotherapy), will be enroled to receive docetaxel :75 mg/m IV day 1 every 3 weeks with nintedanib (vargatef):200 mg X 2/day per os day2-day21. Tumor response (according ...

Phase

0.0 miles

Learn More »

A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma

This is a randomized, open-label (identity of assigned treatment will be known to participants and study staff), 2-arm (2 treatment groups), multicenter study of daratumumab in participants diagnosed with previously untreated Multiple Myeloma who are eligible for high dose chemotherapy and autologous stem cell transplantation (transplantation of own bone marrow). ...

Phase

0.0 miles

Learn More »

Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

This is a phase III study assessing 2 mutli-line therapeutic strategies in patients with unresectable wild-type RAS metastatic colorectal cancer. All the available treatments are being used in each strategy (oxaliplatine, irinotecan, fluoropyrimidines, bevacizumab, cetuximab or panitumumab) but in a different order: STRATEGY A: FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with ...

Phase

0.0 miles

Learn More »

Six Years of Follow-up After Idiopathic Venous Throbmoembolism

Beyond the first 6 months of anticoagulation, patients with a first episode of unprovoked venous thromboembolism have a high risk of recurrence after stopping anticoagulations (about 10% at one year and 30% at 5 years). Extending anticoagulant therapy for an additional 18 months is associated with a major reduction of ...

Phase N/A

0.0 miles

Learn More »

Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway

Secondary objectives are : phase I : to collect preliminary results on the 6-month progression-free rate of the combination vismodegib + temozolomide PHASE II To estimate in the two study arms: the objective response rate (Complete response + Partial Response according to WHO criteria) after 6 months of treatment the ...

Phase

0.0 miles

Learn More »

Efficacy of Ozurdex in the Treatment of Diabetic Macular Edema (DME)

This study will evaluate the efficacy of Ozurdex as prescribed in clinical practice in France for the treatment of Diabetic Macular Edema (DME).

Phase N/A

0.0 miles

Learn More »

Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases

This is a trial comparing two strategies with the aim to determine the best place for cerebral radiotherapy (initially or only systematic progression). Arm A: Initial cerebral radiotherapy and chemotherapy, standard arm Arm B: Chemotherapy and Radiotherapy brain if clinical or radiological cerebral progression , experimental arm (The chemotherapy treatments ...

Phase

0.0 miles

Learn More »

Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte ) in Meningeal Metastasis of Breast Cancer

Patients eligible for the trial and having signed their consent to participate will be randomized to arm A or B. Arm A: Standard systemic treatment without Depocyte Arm B: Standard systemic treatment with Depocyte Patients randomized to arm B will receive an intrathecal injection of Depocyte every 14 2 days ...

Phase

0.0 miles

Learn More »